Unswitch-ABL drugs overcome resistance in chronic myeloid leukemia

摘要

*This article is free to read on the publisher's website*\ud\udABL inhibitors have revolutionized the clinical management of chronic myeloid leukemia, but the BCR-ABLT315I mutation confers resistance to currently approved drugs. Chan et al. show, in this issue of Cancer Cell, that " switch-control" inhibitors block BCR-ABLT315I activity by preventing ABL from switching from the inactive to active conformation.